AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03171350 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ellume.lab Group A Streptococcus Test
Description: ellume.lab Group A Streptococcus Test is a rapid diagnostic test intended to be used as an aid in the diagnosis of Group A Streptococcus in symptomatic patients. The sample type used is a throat swab.
Study NCT01511562 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: stem cell transplant
Study NCT01511562 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: G-CSF
Study NCT01340794 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01340794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib Hydrochloride
Description: Given PO
Study NCT00235755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retigabine
Description: Oral tablet. The starting daily dose will be 300 mg/day administered orally in three equally divided doses. This dosage will be increased by 150 mg/day (50 mg/dose) at 1-week intervals (titration phase). At the beginning of Week 3, patients will enter a 12 week maintenance phase.
Study NCT00235755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retigabine
Description: Oral tablet. The starting daily dose will be 300 mg/day administered orally in three equally divided doses. This dosage will be increased by 150 mg/day (50 mg/dose) at 1-week intervals (titration phase). At the beginning of Week 5, patients will enter a 12 week maintenance phase.
Study NCT00235755 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet.
Study NCT02125500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir/Ledipasvir fixed dose
Description: SOF 400 mg/LDV 90 mg FDC tablet administered orally once daily
Study NCT01978496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eletriptan 20 mg
Description: 20mg oral
Study NCT01978496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eletriptan 40 mg
Description: 40mg oral
Study NCT01978496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eletriptan 80 mg
Description: 80mg oral
Study NCT01167374 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Carbon Ion Radiotherapy
Description: Increasing Dose of Carbon Ion Radiotherapy 4 x 10 Gy E to 4 x 14 Gy E
Study NCT04034784 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Discrete(TM)
Description: A designated volume of Discrete(TM) (according to cohort) is applied intraperitoneally
Study NCT04034784 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control Lactated Ringer's Solution (Control LRS)
Description: A designated volume of LRS (according to cohort and equivalent to volume of Discrete(TM)) is applied intraperitoneally
Study NCT02114463 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local analgesic
Description: Patient will be performed under combined lumbar plexus and sciatic nerve block with 0.33% ropivacaine.At the end of surgery,two catheters are left in the wound.One is intraarticular and the other is on the surface of articular cavity.And then a pump elastomeric infusion pump will be connected with the catheters, which runs 5mL every hours.
Study NCT02114463 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous analgesic
Description: People in this group will also receive an anesthesia of combined lumbar plexus and sciatic nerve block with 0.33% ropivacaine.An intravenous electronic analgesia pump infusion of flurbiprofen axetil 250mg,palonosetron 0.5mg,pentazocine 240mg.dezocine 30mg will will provide postoperative pain management.The patients will received a 2 mL/h continuous basal infusion and 1 mL boluses with a lockout time of 30 min after a 5 mL Loading dose at the end of the surgery.
Study NCT02114463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine
Description: 0.2% ropivacaine
Study NCT02114463 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: flurbiprofen
Description: flurbiprofen axetil 250mg,palonosetron 0.5mg,pentazocine 240mg.dezocine 30mg
Study NCT01153126 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive Health Enhancement Support System (CHESS.)
Description: Half of the participating women will be randomly assigned to usual care and half will be offered a fully CHESS.
Study NCT03485066 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tetris
Description: The video game Tetris is a cognitively challenging task, which requires mental rotation, problem solving and fast visuo-spatial and motor coordination.
Study NCT02921659 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Niagen™
Description: nicotinamide riboside chloride, 250mg capsules
Study NCT02921659 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: silicified microcrystalline cellulose, vegetarian capsule
Study NCT02816697 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CEASE
Description: * Clinical and Community Effort Against Secondhand Smoke Exposure (CEASE)~* CEASE is a system-level intervention that integrates tobacco-use screening, cessation assistance, and referral to outside services into routine visits
Study NCT02816697 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CEASE
Description: * Clinical and Community Effort Against Secondhand Smoke Exposure (CEASE)~* CEASE is a system-level intervention that integrates tobacco-use screening, cessation assistance, and referral to outside services into routine visits
Study NCT02816697 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Tobacco Treatment Services
Study NCT03351517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol 100 MG
Description: 100 mg of oral extended release tapentadol will be given to the patients undergoing total knee replacement surgery on spinal anesthesia to evaluate its efficacy in the management of post-operative pain.
Study NCT03351517 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: A matching placebo will be given to the patients undergoing total knee replacement surgery on spinal anesthesia to evaluate its efficacy in the management of post-operative pain.
Study NCT04416048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Treatment with Rivaroxaban 20 mg (15 mg for subjects with an eGFR ≥30 mL/min/1.73m2 and \<50 mL/min/1.73m2) once daily (OD) for at least 7 days. In case of hospitalization for more than 7 days, the therapeutic treatment with rivaroxaban will be continued for the duration of the hospital stay until discharge. After at least 7 days of therapeutic treatment with rivaroxaban or after hospital discharge, the study dose of rivaroxaban will be adjusted as follows. Patients randomized to the rivaroxaban study arm will reduce daily dosage to 10 mg OD, provided that they were not diagnosed with a condition requiring continued therapeutic anticoagulation. Thromboprophylaxis therapy will be given for 28 days up to day 35 post randomization or even longer. If the patient cannot be discharged from the hospital prior to day 35 post randomization, the thromboprophylaxis phase will also start upon hospital discharge, but is then shorter than 28 days, because the study ends at day 60 post randomization.
Study NCT04416048 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Of Care (SOC)
Description: Standard of care treatment
Study NCT01620086 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Repetitive Transcranial Magnetic Stimulation 1 Hz
Description: active rTMS delivered at 1Hz frequency over temporal cortex
Study NCT01620086 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Repetitive Transcranial Magnetic Stimulation 10 Hz
Description: active rTMS delivered at 10 Hz frequency over temporal cortex
Study NCT01620086 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active control site Repetitive Transcranial Magnetic Stimulation at 1Hz
Description: active rTMS delivered at either 1 Hz frequency over the vertex
Study NCT01620086 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham control site Repetitive Transcranial Magnetic Stimulation
Description: sham rTMS delivered at 1Hz frequency over the vertex
Study NCT01620086 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active control site Repetitive Transcranial Magnetic Stimulation at 10 Hz
Description: Active 10 Hz rTMS delivered over the vertex
Study NCT04494035 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CAPERE Thrombectomy System
Description: Arteriovenous graft thrombectomy
Study NCT03178383 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Project HEAL
Description: Standard group churches will not be asked to, or provided special encouragement to technical assistance with, institutionalizing health promotion activities in their churches.
Study NCT03178383 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project HEAL 2.0
Description: In this approach, rather than developing a separate health ministry, cancer activities could be integrated throughout existing church ministries (e.g. men's, women's, seniors).
Study NCT02005380 — intervention group
Intervention type: OTHER
Intervention: Text-based task
Description: Participants are required to take text-based exercise.
Study NCT02464618 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social contact intervention
Description: The social contact of the patients in this arm will be engaged to improve adherence to out-patient endoscopy
Study NCT02718729 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopic resection for rectal cancer
Description: Formal curative radical laparoscopic rectal resection.
Study NCT01380795 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: CTC
Description: every two cures of a standard chemotherapy patients will be taken sample of blood to monitor CTC presence and EGFR/ K-ras status of that CTC
Study NCT01257516 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pregabalin immediate release, 300 mg
Description: 300 mg immediate release capsule administered twice daily for four days
Study NCT01257516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin controlled release, 330 mg
Description: Two tablets of 330 mg (total dose of 660 mg) given concurrently once daily for four days
Study NCT00684996 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etaracizumab
Description: Given IV
Study NCT00684996 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: Given IV
Study NCT02480283 — intervention group
Intervention type: RADIATION
Intervention: Chest X-ray
Description: To identify any previously undiagnosed lung disease that will either increase the risk of bronchoscopy or confound results of the study.
Study NCT02480283 — intervention group
Intervention type: PROCEDURE
Intervention: Venipuncture
Description: To collect blood cells and serum for analyses.
Study NCT01679691 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: epidural anesthesia
Description: the group in whom all patients will be subjected to epidural anesthesia intra- and post-operative
Study NCT02480283 — intervention group
Intervention type: PROCEDURE
Intervention: Intravenous Catheter
Description: To administer the appropriate medications for the bronchoscopy procedure.
Study NCT02005380 — intervention group
Intervention type: OTHER
Intervention: Graphic-based Task
Description: Participants are required to take the graphic-based exercise.
Study NCT04185155 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simple cognitive task
Description: A memory cue followed by playing the computer game Tetris on own smartphone. Options to engage in self-administered booster sessions after day 1.
Study NCT04185155 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention placebo
Description: Smartphone activity for same amount of time.
Study NCT02102113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo
Study NCT02102113 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: placebo
Study NCT02102113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Very Low Dose THC
Description: Subjects will receive 0.010mg/kg.
Study NCT02102113 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Very Low Dose THC
Description: Subjects will receive 0.010mg/kg.
Study NCT01739036 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ChAd63 CS/ME-TRAP
Description: Mixture of ChAd63 CS 5 x 1010 vp and ChAd63 ME-TRAP 5 x 1010 vp. Intramuscular needle injection.
Study NCT01739036 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MVA CS/ME-TRAP
Description: Mixture of MVA CS 2 x 108 pfu and MVA ME-TRAP 2 x 108 pfu. Intramuscular needle injection.
Study NCT01739036 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ChAd63 CS/ME-TRAP/AMA1
Description: Mixture of ChAd63 CS 5 x 1010 vp, ChAd63 ME-TRAP 5 x 1010 vp, and ChAd63 AMA1 5 x 1010 vp. Intramuscular needle injection.
Study NCT01739036 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MVA CS/ME-TRAP/AMA1
Description: Mixture of MVA CS 1.33 x 108 pfu, MVA ME-TRAP 1.33 x 108 pfu, and MVA AMA1 1.33 x 108 pfu. Intramuscular needle injection.
Study NCT01739036 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Controlled Human Malaria Infection Administered by Mosquito Bite
Description: Approximately three weeks post MVA dosing.
Study NCT03378310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986205 reference tablet
Description: Single, 100 mg oral dose.
Study NCT04242108 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Deep learning algorithm based on AS-OCT scans
Description: The OCT scans of study subjects would be imported into the algorithm. Automated classfication of angle width and detection of synechia would be performed by the algorithm. The diagnostic performance of the algorithm would be compared with gonioscopy records.
Study NCT01674686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarpogrelate
Description: Sarpogrelate 100mg twice a day
Study NCT01674686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin 80mg daily
Study NCT01041625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast (CC-10004)
Description: Apremilast 20 mg tablet PO administered BID over 12 weeks
Study NCT02300324 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standard broccoli and stilton soup
Description: Participants will be randomised to eat one portion (300g) of broccoli soup for each phase.
Study NCT02300324 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beneforte broccoli and stilton soup
Description: Participants will be randomised to eat one portion (300g) of broccoli soup for each phase.
Study NCT02300324 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beneforte Extra broccoli and stilton soup
Description: Participants will be randomised to eat one portion (300g) of broccoli soup for each phase.
Study NCT04450251 — intervention group
Intervention type: OTHER
Intervention: Data Collection
Description: Collect observational fetal electrocardiogram (ECG) readings with a novel wearable device.
Study NCT04945434 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: S53P4 bioactive glass (BonAlive)
Description: Surgical implantation of S53P4 in a bone defect created during debridement for chronic osteomyelitis.
Study NCT03952169 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus paracasei dietary supplement
Description: a commercial probiotic dietary supplement
Study NCT03952169 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo controls
Description: placebo with a similar appearance to probiotics supplement
Study NCT02262351 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 30 Second Pulse Check
Description: To detect atrial fibrillation
Study NCT02262351 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Watch BP Home A
Description: Blood pressure device that detects atrial fibrillation
Study NCT02262351 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HeartCheck Hand-held ECG device
Description: To detect atrial fibrillation
Study NCT03692546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine (LB)
Description: Addition of LB solution to soft tissue surgical field block to a standard interscalene block procedure
Study NCT03607916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric prilocaine 2%
Description: Varying dose according to sensitive response of previous subjects. All study doses of hyperbaric prilocaine 2% will be administrated intrathecally with 100µg of morphine
Study NCT03378310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986205 tablet with free base
Description: Single, 100 mg oral dose.
Study NCT02864121 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: all patients included in IDAHO study
Study NCT03668002 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Arteriovenous Fistula (AVF)
Description: If the participant is randomized to the AVF arm of the trial, the surgeon will connect an artery to a vein in the upper extremity, without using artificial material as conduit.
Study NCT03668002 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arteriovenous Graft (AVG)
Description: If the participant is randomized to the AVG arm of the trial, the surgeon will place a synthetic graft connecting an artery and vein under the skin in an upper extremity.
Study NCT00286494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin and pioglitazone
Description: Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg or 45 mg, tablets, orally, once daily for up to 26 weeks
Study NCT00286494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin and pioglitazone
Description: Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg or 45 mg, tablets, orally, once daily for up to 26 weeks
Study NCT00286494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Alogliptin placebo-matching tablets, orally, once daily and pioglitazone 30 mg or 45 mg, tablets, orally, once daily for up to 26 weeks
Study NCT03436940 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: On Demand Discharge Planning (DDP)
Description: Patients with an intermediate score, according to the simplified Blaylock Risk Assessment Screening Score, are addressed to the NOCC team (hospital Continuity of care team) only in case of a specific request by the unit of hospitalization.
Study NCT03607916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric prilocaine 2%
Description: The dose of 60 mg of Hyperbaric prilocaine 2% will be administrated intrathecally with 100µg of morphine
Study NCT03607916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: 100µg morphine
Study NCT00864162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril10 mg Capsules, single dose
Description: A: Experimental Subjects received Purepac formulated products under fed conditions
Study NCT00864162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atlace® 10 mg capsules, single dose
Description: B: Active comparator Subjects received Monarch Pharmaceuticals Inc. formulated products under fed conditions
Study NCT00859170 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accordion device
Description: an antiretropulsion device
Study NCT00523185 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorazepam
Description: Lorazepam 1 to 2 mg by mouth or intravenously every two hours as needed for alcohol withdrawal symptoms.
Study NCT00523185 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diazepam
Description: Diazepam 20 mg by mouth every two hours x 3 doses, or for parenteral treatment, diazepam 10 mg intravenously every one hour x 6 doses. Give additional diazepam 10 mg by mouth or intravenously every two hours as needed for alcohol withdrawal symptoms.
Study NCT04399161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthwash
Description: A commercially available Chlorhexidine mouth rinse (Hexidine- 0.2 percentage Chlorhexidine gluconate) containing 0.2 percentage chlorhexidine gluconate per 10 ml will be used. 7.5 ml of the concentrate diluted with equal amounts of water to make 15ml will be used for rinsing.
Study NCT04399161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xylitol
Description: Xylitol mouth rinse at 10 percentage concentration will be used. The mouth rinse will be prepared by dissolving 1.5 gm of xylitol powder in 15 ml of water.
Study NCT04399161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Probiotic mouth rinse will be prepared by using a commercially available probiotic product (Sporolac Plus powder- 1gm sachet containing not less than 1.5 billion cells of Lactobacillus acidophilus, Lactobacillus rhamnosus, Bifidobacterium longum, Bacillus coagulans, Saccharomyces boulardii). Each sachet will be dissolved in 15 ml of water in a measuring cup and used as a mouth rinse.
Study NCT02761811 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SyMapCath I™ catheter and SYMPIONEER S1™ Stimulator/Generator
Description: Radiofrequency ablation of renal arterial sympathetic nerves